Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 10/2014

01-10-2014 | Nephrology - Letter to the Editor

Cyclosporin A-induced posterior reversible encephalopathy syndrome in an adolescent with steroid-resistant nephrotic syndrome

Authors: Duygu Övünç Hacihamdioğlu, Aydemir Gökhan, Meral Cihan, Kul Mul, Karademir Ferhan, Selami Süleymanoğlu

Published in: International Urology and Nephrology | Issue 10/2014

Login to get access

Excerpt

Editor, …
Literature
1.
2.
Lewis DM, Tooke JE, Beaman M et al (1998) Peripheral microvascular parameters in the nephrotic syndrome. Kidney Int 54(4):1261–1266PubMedCrossRef
3.
Shuto H, Kataoka Y, Fujisaki K et al (1999) Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci 65(9):879–887PubMedCrossRef
4.
Ishikura K, Hamasaki Y, Sakai T et al (2012) Posterior reversible encephalopathy syndrome in children with kidney diseases. Pediatr Nephrol 27(3):375–384PubMedCrossRef
5.
Iyer RS, Chaturvedi A, Pruthi S et al (2011) Medication neurotoxicity in children. Pediatr Radiol 41(11):1455–1464PubMedCrossRef
Metadata
Title
Cyclosporin A-induced posterior reversible encephalopathy syndrome in an adolescent with steroid-resistant nephrotic syndrome
Authors
Duygu Övünç Hacihamdioğlu
Aydemir Gökhan
Meral Cihan
Kul Mul
Karademir Ferhan
Selami Süleymanoğlu
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 10/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-014-0754-6

Other articles of this Issue 10/2014

International Urology and Nephrology 10/2014 Go to the issue

Urology - Original Paper

Effects of sensory neuron-specific receptor agonist on bladder function in a rat model of cystitis induced by cyclophosphamide

Urology - Original Paper

Long-term durability, functional outcomes, and factors associated with surgical failure of tension-free vaginal tape procedure

Nephrology – Original Paper

AKI in early sepsis is a continuum from transient AKI without tubular damage over transient AKI with minor tubular damage to intrinsic AKI with severe tubular damage

Nephrology - Original Paper

An ignored cause of inflammation in patients undergoing continuous ambulatory peritoneal dialysis: periodontal problems

Urology - Original Paper

Effects of the recreational use of PDE5 inhibitors on the corpus cavernosum of young, healthy rats

Nephrology - Original Paper

Co-administration of Wuzhi capsules and tacrolimus in patients with idiopathic membranous nephropathy: clinical efficacy and pharmacoeconomics
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits